Should we be calling “hormone therapy” for prostate cancer a spade?

When women and their doctors talk about “hormone therapy” they are most commonly referring to the (now) highly controversial issue of whether hormonal supplements (estrogen and progesterone) should be used at and after menopause to prevent the symptoms of menopause and/or later risks related to heart disease and osteoporesis. … READ MORE …

IAD vs. CAD in men with hormone-sensitive, metastatic prostate cancer

Today at the ASCO annual meeting, Maha Hussein presented the results a long-term, international, randomized trial of intermittent androgen deprivation (IAD) versus continuous androgen deprivation (CAD) in men with hormone-sensitive, metastatic prostate cancer. … READ MORE …

Patient satisfaction after first-line treatment for localized prostate cancer (in Germany)

A new article in the journal Anticancer Research suggests that patients had greater satisfaction after modern forms of external beam radiation therapy (EBRT) than after some other standard forms of first-line treatment. Of course the absolute truth of this conclusion may be affected by the details of the study. … READ MORE …

Limited value of immediate, adjuvant ADT in men with pT3b prostate cancer

New data published by clinical researchers at the Mayo Clinic have suggested that there is no overall survival benefit associated with adjuvant hormone therapy after surgery in men with pathological T3b disease. … READ MORE …

Neoadjuvant hormone therapy for patients undergoing first-line radiation therapy

The Irish Clinical Oncology Research Group trial 97-01 was a randomized clinical trial designed to compare the long-term outcomes of patients treated with either 4 months or 8 months of hormonal therapy given before external beam radiotherapy for localized prostate cancer. … READ MORE …

The long-term survival of patients with metastatic prostate cancer

In the late 1980s and early 1990s it was generally considered that men diagnosed with metastatic (but still hormone sensitive) prostate cancer had an estimated survival of 18 to 36 months from the time of diagnosis — including their time on treatment with hormonal therapy. … READ MORE …

Sunday at the ASCO annual meeting

There were a number of significant prostate cancer presentations today, and while none of them were “game changing” (for a variety of reasons), they are certainly worthy of notice. … READ MORE …